RBC Capital analyst Luca Issi maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) yesterday and set a price target of $70.00. The company’s shares closed last Friday at $28.63.
According to TipRanks, Issi is an analyst with an average return of -20.1% and a 27.81% success rate. Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Crispr Therapeutics AG, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Intellia Therapeutics is a Strong Buy with an average price target of $79.60, a 178.03% upside from current levels. In a report released yesterday, BMO Capital also maintained a Buy rating on the stock with a $62.00 price target.
See the top stocks recommended by analysts >>
NTLA market cap is currently $2.56B and has a P/E ratio of -5.35.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTLA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intellia Therapeutics (NTLA) Company Description:
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Read More on NTLA:
- Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- Crispr Therapeutics price target raised to $57 from $50 at RBC Capital
- Intellia Therapeutics files automatic mixed securities shelf
- Intellia Therapeutics receives European Union ODD for NTLA-2002
